GlassScriptPhysician profile
Larry W Thompson
NPI 1497709729
$12,854.38
in general payments reported to CMS, 2019-2025
29 companies · $368 in 2025
The $368 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,197 · 2020: $31.00 · 2021: $5,927 · 2022: $1,620 · 2023: $3,110 · 2024: $602 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,750 · Food and Beverage: $1,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,750.00 |
| Food and Beverage | $1,328.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $8,470.97 | 2021-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $2,432.33 | 2019-2021 | |
| Astellas Pharma US INC | $427.13 | 2019-2025 | Veozah |
| Medtronic, INC. | $339.10 | 2021-2023 | Truclear |
| Minerva Surgical, INC | $176.41 | 2024 | |
| Glaxosmithkline, LLC. | $140.03 | 2022-2025 | Arexvy, Trelegy Ellipta |
| Hologic Sales and Service, LLC | $120.48 | 2021-2024 | Thinprep 2000 Processor, Aptima |
| Lilly USA, LLC | $103.98 | 2024 | Zepbound |
| Sage Therapeutics, LLC | $73.82 | 2023-2025 | Zurzuvae |
| Daiichi Sankyo INC. | $63.00 | 2019-2023 | Injectafer |
| Roche Diagnostics Corporation | $62.45 | 2019 | |
| Exact Sciences Corporation | $55.11 | 2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $52.10 | 2021-2025 | |
| Abbvie INC. | $44.51 | 2019-2024 | |
| Davol INC. | $40.54 | 2023-2025 | Arista |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $36.34 | 2023-2024 | |
| Avion Pharmaceuticals | $30.78 | 2019-2020 | |
| Radiometer America, INC | $28.63 | 2025 | |
| Agile Therapeutics, INC. | $21.87 | 2021 | |
| Ethicon US, LLC | $18.89 | 2025 | Ethicon |
| Amag Pharmaceuticals, INC. | $16.44 | 2019 | |
| Novo Nordisk INC | $15.76 | 2019 | |
| Axonics, INC. | $15.67 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.05 | 2023 | Trulance, Xifaxan |
| Amgen INC. | $14.06 | 2025 | Prolia, Evenity |
| Exeltis, USA INC. | $13.10 | 2023 | Slynd |
| Covidien LP | $12.93 | 2020 | |
| Conmed Corporation | $12.90 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.